BeOne Medicines (BEIGF) Inventory (2017 - 2026)

BeOne Medicines (BEIGF) has reported Inventory for 10 consecutive years, with $732.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory rose 45.69% year-over-year to $732.6 million in Q2 2026; TTM through Jun 2026 was $732.6 million, a 45.69% increase from a year earlier, with the FY2025 full-year figure at $608.2 million, up 22.88% from the prior year.
• Inventory was $732.6 million for Q2 2026 at BeOne Medicines, up from $681.6 million in the prior quarter.
• Over five years, Inventory peaked at $732.6 million in Q2 2026 and troughed at $245.6 million in Q1 2022.
• A 5-year average of $433.4 million and a median of $437.5 million in 2024 frame the typical range for Inventory.
• Across the five-year window, Inventory jumped 236.6% in 2022 and increased 8.94% in 2023, its largest moves.
• Over 5 years, Inventory stood at $282.3 million in 2022, then surged by 47.38% to $416.1 million in 2023, then gained by 18.95% to $495.0 million in 2024, then gained by 22.88% to $608.2 million in 2025, then grew by 20.45% to $732.6 million in 2026.
• The last three Inventory figures came in at $732.6 million (Q2 2026), $681.6 million (Q1 2026), and $608.2 million (Q4 2025), per Business Quant data.